Reports the successful management of rare but lethal acute cardiomyopathy and occlusive thromboembolic events following cisplatin and 5-fluorouracil chemotherapy.
Alerts clinicians to rare cardiotoxicity risks with cisplatin and 5-FU; leaves open optimal management strategies pending further evidence.
Acute development of cardiomyopathy and occlusive thromboembolic events following cisplatin and 5-fluorouracil (5-FU) is rare but frequently lethal. The authors report the successful management of such an event in a 52-year-old man with squamous cell carcinoma of the soft palate. The possible pathophysiological mechanisms are discussed.
No takes yet. Share an insight, caveat, or question.
Cheriparambil et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: